Page 259 - Medicare Benefit Policy Manual
P. 259

G0104 - Colorectal cancer screening; flexible sigmoidoscopy;

                          G0105 - Colorectal cancer screening; colonoscopy on individual at high risk;

                          G0106 - Colorectal cancer screening barium enema; alternative to GO104,
                                   screening sigmoidoscopy;

                          G0120 - Colorectal cancer screening barium enema; alternative to GO105,
                                   screening sigmoidoscopy.

                   B.     Effective for Services Furnished On or After July 1, 2001:

                          G0121 - Colorectal Cancer Screening; Colonoscopy on Individual Not Meeting
                                   Criteria for High Risk

                   C.   Effective for Services Furnished On or After January 1, 2004:

                          G0328 - Colorectal cancer screening; fecal-occult blood test, immunoassay, 1-3
                          simultaneous determinations.

                   280.2.2 - Coverage Criteria
                   (Rev. 11865; Issued:02-16-23; Effective: 01-01-23; Implementation:02-27-23)

                      The following are the coverage criteria for these screenings:

                      A.  Screening Fecal-Occult Blood Tests (FOBT) (Codes 82270 & G0328)

                      Effective for services furnished on or after January 1, 2004, one
                      screening FOBT (code 82270 or G0328) is covered for beneficiaries who
                      have attained age 50, at a frequency of once every 12 months (i.e., at
                      least 11 months have passed following the month in which the last
                      covered screening FOBT was done).  Screening FOBT means: (1) a
                      guaiac-based test for peroxidase activity in which the beneficiary
                      completes it by taking samples from two different sites of three
                      consecutive stools or, (2) an immunoassay (or immunochemical) test for
                      antibody activity in which the beneficiary completes the test by taking
                      the appropriate number of samples according to the specific
                      manufacturer’s instructions.  This expanded coverage is in accordance
                      with revised regulations at 42  CFR 410.37(a)(2) that includes “ other
                      tests determined by the Secretary through a national coverage
                      determination.”  This screening requires a written order from the
                      beneficiary’s attending physician or for claims with dates of service on or
                      after January 27, 2014, from the beneficiary’s attending physician
                      assistant, nurse practitioner, or clinical nurse specialist.  (The term
                      “attending physician” is defined to mean a doctor of medicine or
                      osteopathy (as defined in §1861(r)(1) of the Act) who is fully
   254   255   256   257   258   259   260   261   262   263   264